GENO logo

Genovis AB (publ.) Stock Price

OM:GENO Community·SEK 1.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

GENO Share Price Performance

SEK 19.02
-9.78 (-33.96%)
SEK 19.02
-9.78 (-33.96%)
Price SEK 19.02

GENO Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

0 Risks
2 Rewards

Genovis AB (publ.) Key Details

SEK 0

Revenue

SEK 0

Cost of Revenue

SEK 0

Gross Profit

SEK 0

Other Expenses

SEK 0

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 10, 2026
0.37
89.10%
18.54%
0%
View Full Analysis

About GENO

Founded
1999
Employees
36
CEO
Fredrik Olsson
WebsiteView website
www.genovis.com

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Recent GENO News & Updates

Analysis Article May 01

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Genovis AB (publ.) ( STO:GENO ) shareholders are probably feeling a little disappointed, since its shares fell 4.4% to...

Recent updates

No updates